Apimeds Pharmaceuticals US (APUS) Other Accumulated Expenses (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted Other Accumulated Expenses of $100.0 for Q3 2025, little changed on a QoQ basis from $100.0 in Q2 2025.

Apimeds Pharmaceuticals US (APUS) Other Accumulated Expenses (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $100.0 for Q3 2025.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $100.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $100.0 (changed N/A YoY) and the FY2024 annual result came in at $76500.0, changed N/A from the prior year.
Other Accumulated Expenses was $100.0 for Q3 2025 at Apimeds Pharmaceuticals US, roughly flat from $100.0 in the prior quarter.
Across five years, Other Accumulated Expenses topped out at $93700.0 in Q1 2025 and bottomed at $100.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	89.28 Bn	87.42 Bn	-
2	Teva Pharmaceutical Industries	35.85 Bn	32.11 Bn	1.97 Bn
3	Zoetis	32.48 Bn	30.54 Bn	1.62 Bn
4	Takeda Pharmaceutical	27.52 Bn	23.46 Bn	4.39 Bn
5	United Therapeutics	23.16 Bn	21.01 Bn	648.10 Mn
6	RedHill Biopharma	21.76 Bn	21.76 Bn	-
7	Viatris	20.33 Bn	18.53 Bn	1.16 Bn
8	Neurocrine Biosciences	17.74 Bn	16.43 Bn	800.70 Mn
9	Elanco Animal Health	12.64 Bn	12.21 Bn	785.00 Mn
10	Apimeds Pharmaceuticals US	67.69 Mn	67.69 Mn	-

Download Data